Stockreport

Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF in GA lesion growth versus control at 12 months (P Safety was reported as favorable across 45 subjects, with no treatment-related serious adverse events ; one case of [Read more]